INVESTOR RELATIONS

Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Recent News
Upcoming Events

There are currently no events scheduled.

 
Stock Information
NASDAQ  |  NTLA (Common Stock)
$17.430.00
Stock chart for: NTLA.O.  Currently trading at $17.43 with a 52 week high of $24.90 and a 52 week low of $10.83.
08/23/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
 
IR Contact

Graeme Bell
CFO & Head of Investor Relations
Intellia Therapeutics
+1 857 706 1081
IRcontact@intelliatx.com